NPDUIS Analytical Studies
National Prescription Drug Utilization Information System (NPDUIS) publishes a variety of studies that provide Canadians with comprehensive information on drug pricing, utilization, and cost trends in Canada and internationally. These include annual publications, report series, focused research reports, journal articles, and presentations.
Annual Publications
CompassRx: Annual Public Drug Plan Expenditure Report
9th Edition
Published: December 2023
PDF 1.2 MB
Meds Entry Watch
Meds Pipeline Monitor
2022 Edition
New Published: June 2023
PDF 1.43 MB
Previous Editions
CompassRx: Annual Public Drug Plan Expenditure Report
| Edition | Published | |
|---|---|---|
| CompassRx, 8th Edition, 2020/21 | January 2023 | 908 KB |
| CompassRx, 7th Edition, 2019/20 | November 2021 | 2.5 MB |
| CompassRx, 6th Edition, 2018/19 | December 2020 | 2.4 MB |
| CompassRx, 5th Edition, 2017/18 | September 2019 | 2.25 MB |
| CompassRx, 4th Edition, 2016/17 | September 2018 | 2.80 MB |
| CompassRx, 3rd Edition, 2015/16 | May 2017 | 2.26 MB |
| CompassRx, 2nd Edition, 2013/14 | May 2016 | 4.02 MB |
| CompassRx, 1st Edition, 2012/13 | March 2015 | 4.37 MB |
| Analysis Brief: CompassRx, 2012/13 | March 2015 | 804 KB |
Meds Entry Watch
| Meds Entry Watch Edition | Published | |
|---|---|---|
| 6th Edition | April 2022 | PDF 592 KB |
| 5th Edition, 2019 | February 2021 | 4.7 MB |
| 2018 Edition | January 2020 | 899 KB |
| 2017 Edition | February 2019 | 3.35 MB |
| 2016 Edition | June 2018 | 758 KB |
| 2015 Edition | April 2017 | 2.33 MB |
Meds Entry Watch - Supplementary Information
Meds Pipeline Monitor
| Meds Pipeline Monitor Edition | Published | |
|---|---|---|
| 2021 Edition | April 2022 | 2.7 MB |
| 2020 Edition | January 2021 | 4.1 MB |
| 2019 Edition | April 2020 | 2.4 MB |
| 2018 Edition | May 2019 | 1.94 MB |
| New Drug Pipeline Monitor | ||
| 7th Edition | December 2015 | 1.43 MB |
| 6th Edition | December 2014 | 723 KB |
| 5th Edition | December 2013 | - |
| 4th Edition | April 2013 | - |
| 3rd Edition | July 2011 | - |
| 2nd Edition | July 2008 | - |
| 1st Edition | June 2007 | - |
Report Series
Formularies in Canada
Part 3: Medicines Assessed by the Common Drug Review
Published: February 2022
PDF 1.9 MB
Generics360: Generic Drugs in Canada
2018 Edition
Published: August 2019
PDF 1.10 MB
Market Intelligence Report
Antidiabetic Drugs, 2012-2021
Published: May 2023
2.1 MB
Private Drug Plans in Canada
Part 1: Generic Market 2005–2013
Published: December 2015
PDF 3.02 MB
Previous Editions
Formularies in Canada
| Formularies in Canada Edition | Published | |
|---|---|---|
| Part 2: Oncology Medicines | May 2021 | 2 MB |
| Part 1: General Overview | October 2017 | 2.07 MB |
| List of Selected Drugs | October 2017 | 1 MB |
Generics360: Generic Drugs in Canada
| Generics360: Generic Drugs in Canada Report | Published | |
|---|---|---|
| Generics360: Generic Drugs in Canada - 2016 Edition | February 2018 | 1.19 MB |
| Generics360: Generic Drugs in Canada - 2014 Edition | February 2016 | 1.76 MB |
| Generic Drugs in Canada, 2013 | December 2014 | 645 KB |
| Analysis Brief: Generic Drugs in Canada, 2013 | December 2014 | 182 KB |
| Analytical Snapshot: International Generic Price Comparison, Early 2011 | August 2013 | 899 KB |
| Generic Drugs in Canada: International Price Comparisons and Potential Cost Savings | September 2011 | 368 KB |
| Generic Drugs in Canada: Market Structure – Trends and Impacts | December 2010 | 310 KB |
| Generic Drugs in Canada: Price Trends and International Price Comparisons, 2007 | December 2010 | 415 KB |
Market Intelligence Report
| Market Intelligence Report Report | Published | |
|---|---|---|
| Combination Inhalers for Asthma, 2018 | April 2020 | 4 MB |
| Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs for Retinal Conditions, 2017 | December 2018 | 1 MB |
| Biologic Response Modifier Agents, 2015 - Supplement: 2017 | September 2018 | 875 KB |
| Biologic Response Modifier Agents, 2015 | October 2016 | 2.71 MB |
Focused Reports
Chartbook
Report
Drug Shortages in Canada and their Impact on Public Drug Plans, 2017/18 to 2019/20
Published: September 2022
PDF 710 KB
Previous chartbooks and reports
Previous Chartbooks
| Expensive Drugs for Rare Diseases Chartbook | Published | |
|---|---|---|
| Oncology Medicines in Canada: Trends and International Comparisons, 2010–2019 | October 2020 | 1.5 MB |
| Biologics in Canada, 2018 | May 2020 | - |
| Part 1: Market Trends | May 2020 | 1.35 MB |
| Part 2: Biosimiliar Savings | May 2020 | 387 KB |
| The market for prescription oral solid opioids, 2010 to 2017 | January 2019 | 893 KB |
Previous Reports
| EDrug Shortages in Canada Previous Reports | Published | |
|---|---|---|
| Utilization of Prescription Opioids in Canada's Public Drug Plans, 2006/07 to 2012/13 | April 2014 | 3.07 MB |
| The Drivers of Prescription Drug Expenditures – A Methodological Report | December 2013 | 1.54 MB |
| The Use of Blood Glucose Test Strips in Select Public Drug Plans, 2008 | April 2013 | 666 KB |
| Wholesale Up-charge Policies of Canada's Public Drug Plans | December 2011 - Revised January 2012 | 260 KB |
| The Impact of Generic Entry on the Utilization of the Ingredient | September 2011 - Revised May 2012 | 800 KB |
| Public Drug Plan Dispensing Fees: A Cost-Driver Analysis, 2001/02 to 2007/08 | September 2011 | 813 KB |
| Baby-Boomer Effect on Prescription Expenditures and Claims | December 2010 | 545 KB |
| Use of the World Health Organization Defined Daily Dose in Canadian Drug Utilization and Cost Analyses | December 2010 | 838 KB |
Journal Articles
2023
- Gaudette, É., Rizzardo, S., Wladyka, S.B., Rahman, T., Pothier, K.R. 2023. Is Canada Missing Out? An Assessment of Drugs Approved Internationally Between 2016 and 2020 and Not Submitted for Health Canada Review. CMAJ, 195 (23), E815-E820; DOI: 10.1503/cmaj.230339.
Posters & Presentations
Previous Posters
2022
2021
2019
2018
2017
| Posters & Presentations Posters | |
|---|---|
| Potential Savings from Biosimilars in Canada | 1.56 MB |
| The Canadian Market for Biologic Response Modifier Agents, 2015 | 305 KB |
| Generic Drugs in Canada, 2015 | 369 KB |
| A Review of Public Coverage of CDR Reviewed Drugs | 354 KB |
| A Review of Public and Private Coverage of iJODR/pCODR Reviewed Drugs | 325 KB |
| Potential Savings from Biosimilars in Canada | 440 KB |
2016
2015
2014
Supporting Information
These documents provide background material to supplement the NPDUIS analytical studies:
Canadian Public Drug Plan Designs and Policies
Resources
Reference Documents
Methods
Foreign-to-Canadian Price RatiosPDF 176 KB
General Information
Budget Impact Analysis Guidelines
Page details
- Date modified: